|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/04/22 Passage BIO, Inc. 10-Q 6/30/22 58:6.6M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.86M
2: EX-10.1 Material Contract HTML 87K
3: EX-10.2 Material Contract HTML 42K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
13: R1 Document and Entity Information HTML 73K
14: R2 Balance Sheets HTML 107K
15: R3 Balance Sheets (Parenthetical) HTML 25K
16: R4 Statements of Operations and Comprehensive Loss HTML 71K
17: R5 Statements of Stockholders' Equity HTML 84K
18: R6 Statements of Stockholders' Equity (Parenthetical) HTML 18K
19: R7 Statements of Cash Flows HTML 103K
20: R8 Nature of Operations HTML 21K
21: R9 Risks and Liquidity HTML 22K
22: R10 Summary of Significant Accounting Policies HTML 40K
23: R11 Cash, cash equivalents and marketable securities HTML 111K
24: R12 Fair Value of Financial Instruments HTML 112K
25: R13 Property and Equipment, net HTML 36K
26: R14 Accrued Expenses and Other Current Liabilities HTML 32K
27: R15 Leases HTML 54K
28: R16 Commitments and Contingencies HTML 32K
29: R17 Share-Based Compensation HTML 99K
30: R18 Subsequent Events HTML 20K
31: R19 Summary of Significant Accounting Policies HTML 61K
(Policies)
32: R20 Summary of Significant Accounting Policies HTML 28K
(Tables)
33: R21 Cash, cash equivalents and marketable securities HTML 112K
(Tables)
34: R22 Fair Value of Financial Instruments (Tables) HTML 108K
35: R23 Property and Equipment, net (Tables) HTML 34K
36: R24 Accrued Expenses and Other Current Liabilities HTML 32K
(Tables)
37: R25 Leases (Tables) HTML 49K
38: R26 Share-Based Compensation (Tables) HTML 96K
39: R27 Risks and Liquidity (Details) HTML 30K
40: R28 Summary of Significant Accounting Policies HTML 35K
(Details)
41: R29 Cash, cash equivalents and marketable securities - HTML 31K
Portfolio of Cash and Cash Equivalents (Details)
42: R30 Cash, cash equivalents and marketable securities - HTML 43K
Portfolio of Marketable Securities (Details)
43: R31 Fair Value of Financial Instruments (Details) HTML 55K
44: R32 Property and Equipment, net (Details) HTML 39K
45: R33 Accrued Expenses and Other Current Liabilities HTML 30K
(Details)
46: R34 Leases (Details) HTML 80K
47: R35 Leases - Operating lease cost (Details) HTML 26K
48: R36 Commitments and Contingencies - Collaboration HTML 65K
Agreements (Details)
49: R37 Share-Based Compensation - Equity Incentive Plan & HTML 62K
ESPP (Details)
50: R38 Share-Based Compensation - Share-based HTML 28K
compensation expense (Details)
51: R39 Share-Based Compensation - Stock Option Activity HTML 67K
(Details)
52: R40 Share-Based Compensation - Assumptions Used in HTML 25K
Determining Fair Value & Early exercise of Stock
Options (Details)
53: R41 Share-Based Compensation - Restricted Stock Units HTML 46K
(Details)
56: XML IDEA XML File -- Filing Summary XML 97K
54: XML XBRL Instance -- pasg-20220630x10q_htm XML 1.41M
55: EXCEL IDEA Workbook of Financial Reports XLSX 92K
9: EX-101.CAL XBRL Calculations -- pasg-20220630_cal XML 116K
10: EX-101.DEF XBRL Definitions -- pasg-20220630_def XML 316K
11: EX-101.LAB XBRL Labels -- pasg-20220630_lab XML 905K
12: EX-101.PRE XBRL Presentations -- pasg-20220630_pre XML 597K
8: EX-101.SCH XBRL Schema -- pasg-20220630 XSD 121K
57: JSON XBRL Instance as JSON Data -- MetaLinks 270± 415K
58: ZIP XBRL Zipped Folder -- 0001558370-22-012042-xbrl Zip 463K
Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Edgar B. Cale, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of Passage Bio, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| | |
Date: August 4, 2022 | | |
| | |
| /s/ Edgar B. Cale | |
Interim Chief Executive Officer and General Counsel | ||
(Interim Principal Executive Officer) | ||
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/4/22 | None on these Dates | ||
| For Period end: | 6/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/04/24 Passage BIO, Inc. 10-K 12/31/23 73:10M Toppan Merrill Bridge/FA 3/06/23 Passage BIO, Inc. 10-K 12/31/22 70:9M Toppan Merrill Bridge/FA |